1-(4-klorofenil)-3-metil-5-{4-[(2-metilfenil)metoksi]fenil}-1H-pirazol’ün Kristal Yapısı ve Hirshfeld Yüzey Analizi
Abstract
Keywords
Kristal yapı, Antikanser, Pirazol halkası, C-H··· π etkileşimleri, Hirshfeld yüzey analizi
Supporting Institution
Project Number
Thanks
References
- [1] F. Şen, “4-(3-metil-3-fenilsiklobütil)-2-(2-(piridin-4-ylmetilen)hidrazinil) tiyazol’un sentezi, karakterizasyonu, kristalografik yapısı ve Hirshfeld yüzeyinin incelenmesi,” Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi, c. 8, s. 1, ss. 157–168, 2018.
- [2] M. R. Yadav, P. Murumkar, and R. Ghuge, Vicinal Diaryl Substituted Heterocycles, 1st ed., Oxford, UK: Elsevier, 2018, pp. 1–20.
- [3] E. Banoglu, E. Celikoglu, S. Volker, A. Olgac, J. Gerstmeier, U. Garscha, B. Caliskan, U. S. Schubert, A. Carotti, A. Macchiarulo, and O. Werz, “4, 5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP),” European Journal of Medicinal Chemistry, vol. 113, pp. 1–10, 2016.
- [4] B. Caliskan, S. Luderer, Y. Ozkan, O. Werz and E. Banoglu, “Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils,” European Journal of Medicinal Chemistry, vol. 46, no. 10, pp. 5021–5033, 2011.
- [5] Y. Dundar, S. Unlu, E. Banoglu, A. Entrena, G. Costantino, M. T. Nunez, F. Ledo, M. F. Sahin, and N. Noyanalpan, “Synthesis and biological evaluation of 4,5-diphenyloxazolonederivatives on route towards selective COX-2 inhibitors,” European Journal of Medicinal Chemistry, vol. 44, pp. 4785–4785, 2009.
- [6] G. Eren, S. Unlu, M. T. Nunez, L. Labeaga, F. Ledo, A. Entrena, E. Banoglu, G. Costantino, and M. F. Sahin, “Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors,” Bioorg. Med. Chem., vol. 18, no. 17, pp. 6367–6376, 2010.
- [7] B. C. Ergun, M. T. Nunez, L. Labeaga, F. Ledo, J. Darlington, G. Bain, B. Cakir, and E. Banoglu, “Synthesis of 1,5-diarylpyrazol-3-propanoic acids towards inhibition of cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4 formation,” Arzneimittel-forschung, vol. 60, no. 8, 497–505, 2010.
- [8] U. Garscha, S. Voelker, S. Pace, J. Gerstmeier, B. Emini, S. Liening, A. Rossi, C. Weinigel, S. Rummler, U. S. Schubert, G. K. Scriba, E. Celikoglu, B. Caliskan, E. Banoglu, L. Sautebin, and O. Werz, “BRP-187: A potent inhibitor of leukotriene biosynthesis that acts through impeding the dynamic 5-lipoxygenase/5-lipoxygenase-activating protein (FLAP) complex assembly,” Biochemical Pharmacology, vol. 119, no. 17–26, 2016.
- [9] S. Levent, B. Caliskan, M. Ciftci, Y. Ozkan, I. Yenicesu, H. Unver, and E. Banoglu, “Pyrazole derivatives as inhibitors of arachidonic acid-induced platelet aggregation,” European Journal of Medicinal Chemistry, vol. 64, pp. 42–53, 2013.
- [10] S. C. Pirol, B. Caliskan, I. Durmaz, R. Atalay, and E. Banoglu, “Synthesis and preliminary mechanistic evaluation of 5-(p-tolyl)-1-(quinolin-2-yl)pyrazole-3-carboxylic acid amides with potent antiproliferative activity on human cancer cell lines,” European Journal of Medicinal Chemistry, vol. 87, pp. 140–149, 2014.